Neil Kumar is Chief Executive Officer of BridgeBio Pharma, Inc.. Currently has a direct ownership of 4.9 Million shares of BBIO, which is worth approximately $130 Million. The most recent transaction as insider was on Nov 19, 2024, when has been sold 27,389 shares (Common Stock) at a price of $22.58 per share, resulting in proceeds of $618,443. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.9M
0% 3M change
1.75% 12M change
Total Value Held $130 Million

Neil Kumar Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 19 2024
SELL
Open market or private sale
$618,443 $22.58 p/Share
27,389 Reduced 0.56%
4,897,443 Common Stock
Nov 16 2024
SELL
Payment of exercise price or tax liability
$667,670 $23.72 p/Share
28,148 Reduced 0.57%
4,924,832 Common Stock
Nov 16 2024
BUY
Exercise of conversion of derivative security
-
55,537 Added 1.11%
4,952,980 Common Stock
Aug 19 2024
SELL
Open market or private sale
$678,151 $24.76 p/Share
27,389 Reduced 0.56%
4,897,443 Common Stock
Aug 16 2024
SELL
Payment of exercise price or tax liability
$686,811 $24.4 p/Share
28,148 Reduced 0.57%
4,924,832 Common Stock
Aug 16 2024
BUY
Exercise of conversion of derivative security
-
55,537 Added 1.11%
4,952,980 Common Stock
May 16 2024
SELL
Payment of exercise price or tax liability
$954,417 $31.04 p/Share
30,748 Reduced 0.62%
4,897,443 Common Stock
May 16 2024
BUY
Exercise of conversion of derivative security
-
60,667 Added 1.22%
4,928,191 Common Stock
Feb 16 2024
SELL
Payment of exercise price or tax liability
$1,783,177 $37.21 p/Share
47,922 Reduced 0.97%
4,867,524 Common Stock
Feb 16 2024
BUY
Exercise of conversion of derivative security
-
102,249 Added 2.04%
4,915,446 Common Stock
Nov 17 2023
SELL
Open market or private sale
$1,512,020 $29.33 p/Share
51,552 Reduced 1.06%
4,813,197 Common Stock
Nov 16 2023
SELL
Payment of exercise price or tax liability
$1,463,115 $28.86 p/Share
50,697 Reduced 1.03%
4,864,749 Common Stock
Nov 16 2023
BUY
Exercise of conversion of derivative security
-
102,249 Added 2.04%
4,915,446 Common Stock
Aug 17 2023
SELL
Open market or private sale
$1,473,871 $28.59 p/Share
51,552 Reduced 1.06%
4,813,197 Common Stock
Aug 16 2023
SELL
Payment of exercise price or tax liability
$1,510,800 $29.8 p/Share
50,698 Reduced 1.03%
4,864,749 Common Stock
Aug 16 2023
BUY
Exercise of conversion of derivative security
-
102,250 Added 2.04%
4,915,447 Common Stock
May 17 2023
SELL
Open market or private sale
$722,243 $14.01 p/Share
51,552 Reduced 1.06%
4,813,197 Common Stock
May 16 2023
SELL
Payment of exercise price or tax liability
$714,320 $14.09 p/Share
50,697 Reduced 1.03%
4,864,749 Common Stock
May 16 2023
BUY
Exercise of conversion of derivative security
-
102,249 Added 2.04%
4,915,446 Common Stock
Feb 17 2023
SELL
Open market or private sale
$568,934 $12.7 p/Share
44,798 Reduced 0.92%
4,813,197 Common Stock
Feb 16 2023
SELL
Payment of exercise price or tax liability
$302,197 $12.64 p/Share
23,908 Reduced 0.49%
4,857,995 Common Stock
Feb 16 2023
BUY
Exercise of conversion of derivative security
-
68,706 Added 1.39%
4,881,903 Common Stock
Nov 17 2022
SELL
Open market or private sale
$325,616 $9.4 p/Share
34,640 Reduced 0.71%
4,813,197 Common Stock
Nov 16 2022
SELL
Payment of exercise price or tax liability
$328,396 $9.64 p/Share
34,066 Reduced 0.7%
4,847,837 Common Stock
Nov 16 2022
BUY
Exercise of conversion of derivative security
-
68,706 Added 1.39%
4,881,903 Common Stock
NK

Neil Kumar

Chief Executive Officer
Palo Alto, CA

Track Institutional and Insider Activities on BBIO

Follow BridgeBio Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BBIO shares.

Notify only if

Insider Trading

Get notified when an Bridge Bio Pharma, Inc. insider buys or sells BBIO shares.

Notify only if

News

Receive news related to BridgeBio Pharma, Inc.

Track Activities on BBIO